Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 7/20 | 0.36 |
| ▸ | PPME1 | Q9Y570 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | APEH | P13798 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388837 | 0.88 | ENPP3 (0.40) | BRD4ENPP3ENPP1 | |
| SCHEMBL4191193 | 0.86 | BRD4 (0.39) | BRD4ENPP3ENPP1HTR6DRD2 | |
| SCHEMBL8298982 | 0.85 | BRD4 (0.41) | BRD4IMPDH2HTR6PPME1DRD2 | |
| SCHEMBL14976342 | 0.82 | SCN5A (0.39) | BRD4HTR6DRD2HTR2AHTR7 | |
| SCHEMBL2965430 | 0.81 | BRD4 (0.47) | BRD4ENPP3ENPP1HTR6DRD2 | |
| SCHEMBL1043519 | 0.81 | BRD4 (0.58) | BRD4ENPP3ENPP1HTR6DRD2 | |
| SCHEMBL13620691 | 0.80 | HTR6 (0.53) | BRD4ENPP3ENPP1HTR6DRD2 | |
| SCHEMBL4196067 | 0.79 | KDM4E (0.45) | BRD4ENPP3ENPP1HTR6DRD2 | |
| SCHEMBL1796808 | 0.79 | AKR1C3 (0.56) | BRD4ENPP3ENPP1HTR6DRD2 | |
| SCHEMBL9280138 | 0.79 | PDPK1 (0.49) | BRD4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612086-B2 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612086-B2 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| WO-2008110508-A1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INAPPROPRIATE IKK1 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110508-A1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INAPPROPRIATE IKK1 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | WO | disclosed |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1628975-A2 | JNK INHIBITORS | Eisai Co., Ltd. (JP) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004101565-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | API5, MAP3K5, MAP3K7 | BRD4 469/4885ENPP3 2154/4885ENPP1 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.